share_log

Piper Sandler Maintains Overweight on Day One Biopharmaceutical, Maintains $40 Price Target

Moomoo 24/7 ·  Mar 26 07:59

Piper Sandler analyst Joseph Catanzaro maintains Day One Biopharmaceutical (NASDAQ:DAWN) with a Overweight and maintains $40 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment